Lobbying client
OCERA THERAPEUTICS INC.
Biopharmaceutical product development & research
Filings
14
Filed by
1
Reported in-house
—
Reported by firms
$260,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2008 to 2010
Filings
14 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
1st Quarter - Termination Amendment 1st Quarter 2010
|
FABIANI & COMPANY | — reported |
|
1st Quarter - Termination Amendmentreplaced 1st Quarter 2010
|
FABIANI & COMPANY | — reported |
|
1st Quarter - Terminationreplaced 1st Quarter 2010
|
FABIANI & COMPANY | — reported |
|
4th Quarter - Amendment 4th Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
|
4th Quarter - Amendmentreplaced 4th Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
|
3rd Quarter - Amendment 3rd Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
|
4th Quarter - Reportreplaced 4th Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
|
3rd Quarter - Amendmentreplaced 3rd Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
|
3rd Quarter - Reportreplaced 3rd Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
|
3rd Quarter - Reportreplaced 3rd Quarter 2009
|
FABIANI & COMPANY | $60,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FABIANI & COMPANY | 6 | $260,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Defense | DEF | 7 |
| Health Issues | HCR | 7 |
| Budget/Appropriations | BUD | 5 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.